Laboratorio Lemos S.R.L. is a biotechnology company dedicated to the development, elaboration and commercialization of simple, precise and reliable tools to solve biomedical problems that mainly affect developing countries. The main area of interest of Laboratorio Lemos S.R.L. It is the Chagas disease, an endemic disease that affects 18 countries, and whose etiological agent is the Trypanosoma cruzi parasite. Laboratorio Lemos S.R.L. manufactures and markets various in vitro diagnostic products, as well as epidemiological tools, which allow the detection and monitoring of individuals infected with Trypanosoma cruzi with a high degree of sensitivity and specificity.
The central problem of Chagas disease is that, as in most cases it presents as an asymptomatic desease, approximately 30% of those infected develop cardiomyopathy that can lead to sudden death or progressive heart failure. Although there are no vaccines to prevent the disease, infected children can be cured by means of parasiticidal drugs. For this reason, the greatest efforts in the research area of Laboratorio Lemos S.R.L. are aimed at developing new diagnostic methods that facilitate the massive and early identification of all children infected with Trypanosoma cruzi, as well as the monitoring of the therapeutic-curative dynamics, and the evolution of the pathology and its clinical consequences.